We are live on ! Find out more
HVC

Healthcare Value Capital Portfolio holdings

AUM $50.7M
1-Year Est. Return 24.72%
This Fund
S&P 500
This Quarter Est. Return
-1.29%
1 Year Est. Return
+24.72%
3 Year Est. Return
+18.99%
5 Year Est. Return
+98.49%
10 Year Est. Return
–
AUM
$119M
AUM Growth
-$33.6M
Cap. Flow
+$4.33M
Cap. Flow %
3.64%
Top 10 Hldgs %
74.7%
Holding
51
New
6
Increased
12
Reduced
5
Closed
18

Top Buys

Rank Stock Value
1
AZN icon
AstraZeneca
AZN
+$3.09M
2
ANIP icon
ANI Pharmaceuticals
ANIP
+$2.05M
3
PFE icon
Pfizer
PFE
+$1.5M
4
IPXL
Impax Laboratories, Inc.
IPXL
+$1.35M
5
BIS icon
ProShares UltraShort NASDAQ Biotechnology
BIS
+$1.29M

Top Sells

Rank Stock Value
1
QLTI
QLT Inc
QLTI
+$3.48M
2
HNT
HEALTH NET INC
HNT
+$3.4M
3
SUPN icon
Supernus Pharmaceuticals
SUPN
+$951K
4
BAX icon
Baxter International
BAX
+$736K
5
VIRX
Viracta Therapeutics, Inc. Common Stock
VIRX
+$570K

Sector Composition

Rank Sector Weight
1 Miscellaneous 52.77%
2 Healthcare 47.23%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ZGNX
26
DELISTED
Zogenix, Inc.
ZGNX
$503K 0.42%
31,250
+18,750
+150% +$339K
GLMD icon
27
Galmed Pharmaceuticals
GLMD
$4.49M
$487K 0.41%
35
– –
ARIA
28
DELISTED
Ariad Pharmaceuticals Inc
ARIA
$478K 0.4%
+75,000
New +$516K
VXRT
29
DELISTED
Vaxart
VXRT
$415K 0.35%
13,228
-9,091
-41% -$380K
RIGL icon
30
Rigel Pharmaceuticals
RIGL
$875M
$363K 0.3%
10,000
-5,000
-33% -$170K
IMNN icon
31
Imunon
IMNN
$8.98M
$347K 0.29%
37
-18
-33% -$161K
STML
32
DELISTED
Stemline Therapeutics, Inc.
STML
$242K 0.2%
16,464
– –
CYTK icon
33
Cytokinetics
CYTK
$10.8B
$199K 0.17%
41,666
-15,000
-26% -$91.5K
BAX icon
34
CALL
Baxter International
BAX
$13.4B
– –
-184,100
Closed -$7.36M
BAX icon
35
Baxter International
BAX
$13.4B
– –
-18,410
Closed -$736K
FOLD
36
DELISTED
Amicus Therapeutics
FOLD
– –
-200,000
Closed -$414K
MDY icon
37
PUT
State Street SPDR S&P MIDCAP 400 ETF Trust
MDY
$26.7B
– –
-50,000
Closed -$12.5M
SUPN icon
38
Supernus Pharmaceuticals
SUPN
$2.57B
– –
-106,735
Closed -$951K
TEVA icon
39
CALL
Teva Pharmaceuticals
TEVA
$43.8B
– –
-75,000
Closed -$3.96M
VIRX
40
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
– –
-491
Closed -$570K
AMAG
41
CALL
DELISTED
AMAG Pharmaceuticals
AMAG
– –
-20,000
Closed -$387K
WCG
42
PUT
DELISTED
Wellcare Health Plans, Inc.
WCG
– –
-125,000
Closed -$7.94M
QLTI
43
CALL
DELISTED
QLT Inc
QLTI
– –
-200,000
Closed -$1.11M
QLTI
44
DELISTED
QLT Inc
QLTI
– –
-626,639
Closed -$3.48M
HNT
45
CALL
DELISTED
HEALTH NET INC
HNT
– –
-100,000
Closed -$3.4M
HNT
46
DELISTED
HEALTH NET INC
HNT
– –
-100,000
Closed -$3.4M
ZGNX
47
CALL
DELISTED
Zogenix, Inc.
ZGNX
– –
-25,000
Closed -$569K
PCYC
48
PUT
DELISTED
PHARMACYCLICS INC
PCYC
– –
-10,000
Closed -$1M
ITMN
49
CALL
DELISTED
INTERMUNE INC
ITMN
– –
-50,000
Closed -$1.67M
FURX
50
DELISTED
FURIEX PHARMACEUTICALS INC COM STK (DE)
FURX
– –
-5,000
Closed -$435K
1
2
3

Similar funds

C
Castlelake Minneapolis, Minnesota $48.5M AUM 87.77% 1-Year Est. Return
CC
Cedar Capital Barrington, Illinois $54.9M AUM 33.3% 1-Year Est. Return
FCOI
FirstMark Capital OF II New York $44.1M AUM 18.15% 1-Year Est. Return
FCOI
FirstMark Capital OF I New York $43.1M AUM 6.31% 1-Year Est. Return
BI
BCBSM Inc Eagan, Minnesota $42.4M AUM 0.4% 1-Year Est. Return
KC
Kelso & Company New York $42.3M AUM
SCIM
Spring Creek Investment Management Philadelphia, Pennsylvania $42.3M AUM 31.86% 1-Year Est. Return
MCP
Moab Capital Partners Southampton, New York $41M AUM 33.21% 1-Year Est. Return

Healthcare Value Capital's Q2 2014 Portfolio in Review

As of Q2 2014, Healthcare Value Capital held 51 positions worth $119M, down 22% from $153M the previous quarter. Its ten largest holdings account for 75% of the portfolio.

Healthcare Value Capital deployed $4.33M of net new capital in Q2 2014, opening 6 new positions and adding to 12 existing holdings. Its largest new stake was Impax Laboratories, Inc.: 50,000 shares worth $1.5M.

By sector, the portfolio is most concentrated in Miscellaneous at 53% of assets, down from 65% a quarter earlier, followed by Healthcare.

On the sell side, the largest reduction was Vaxart, an estimated $380K trimmed.

  • Healthcare Value Capital's largest Q2 2014 buy was Impax Laboratories, Inc.: 50,000 shares worth $1.5M.
  • Healthcare Value Capital added most to AstraZeneca in Q2 2014, an estimated $3.09M increase.
  • Healthcare Value Capital's biggest Q2 2014 reduction was Vaxart, cutting an estimated $380K.
  • Healthcare Value Capital fully exited QLT Inc in Q2 2014, selling an estimated $3.48M.
  • Healthcare Value Capital's ten largest holdings make up 75% of its $119M portfolio in Q2 2014.
  • Healthcare Value Capital opened 6 new positions and closed 18 in Q2 2014.
  • Healthcare Value Capital's portfolio value fell 22% quarter-over-quarter to $119M.

Based on Healthcare Value Capital's 13F filing for Q2 2014, filed 13 Aug 2014.